Alterations of phospholamban function can exhibit cardiotoxic effects independent of excessive sarcoplasmic reticulum Ca2+-ATPase inhibition

Circulation

Volumn 119, Issue 3, 2009, Pages 436-444

  Schmitt, Joachim P ^a   Ahmad, Ferhaan ^b,g   Lorenz, Kristina ^a   Hein, Lutz ^a,c   Schulz, Stefan ^d   Asahi, Michio ^e   MacLennan, David H ^e   Seidman, Christine E ^f,g   Seidman, J G ^g   Lohse, Martin J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e UNIVERSITY OF TORONTO   (Canada)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Calcium; Cardiomyopathy; Heart failure; Sarcoplasmic reticulum

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; ISOPRENALINE; MUTANT PROTEIN; PHOSPHOLAMBAN; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; CALCIUM BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM TRANSPORT; CARDIOTOXICITY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DOSAGE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; AMINO ACID SUBSTITUTION; ANIMAL; BIOSYNTHESIS; CELL LINE; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; TRANSGENIC MOUSE;

AMINO ACID SUBSTITUTION; ANIMALS; CALCIUM-BINDING PROTEINS; CELL LINE; HEART FAILURE; HUMANS; MICE; MICE, TRANSGENIC; PHOSPHORYLATION; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES;

EID: 60549086753     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.108.783506     Document Type: Article

References (22)

1. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell. 2001;104:557-567.
2. Schmitt JP, Debold EP, Ahmad F, Armstrong A, Frederico A, Conner DA, Mende U, Lohse MJ, Warshaw D, Seidman CE, Seidman JG. Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function. Proc Natl Acad Sci U S A. 2006;103:14525-14530.
3. Gramolini AO, Kislinger T, Alikhani-Koopaei R, Fong V, Thompson NJ, Isserlin R, Sharma P, Oudit GY, Trivieri MG, Pagan A, Kannan A, Higgins DG, Huedig H, Hess G, Arab S, Seidman JG, Seidman CE, Frey B, Perry M, Backx PH, Liu PP, MacLennan DH, Emili A. Comparative proteomics profiling of a phospholamban mutant mouse model of dilated cardiomyopathy reveals progressive intracellular stress responses. Mol Cell Proteomics. 2008;7:519-533.
4. Schmitt JP, Kamisago M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman JG, Seidman CE. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science. 2003;299:1410-1413.
5. MacLennan DH, Kranias EG. Phospholamban: a crucial regulator of cardiac contractility. Nat Rev. 2003;4:566-577.
6. Vittone L, Mundina C, Chiappe de Cingolani G, Mattiazzi A. cAMP and calcium-dependent mechanisms of phospholamban phosphorylation in intact hearts. Am J Physiol. 1990;258:H318-H325.
7. Luo W, Chu G, Sato Y, Zhou Z, Kadambi VJ, Kranias EG. Transgenic approaches to define the functional left ventricular role of dual site phospholamban phosphorylation. J Biol Chem. 1998;273:4734-4739.
8. Hasenfuss G, Pieske B. Calcium cycling in congestive heart failure. J Mol Cell Cardiol. 2002;34:951-969.
9. Kadambi VJ, Ponniah S, Harrer JM, Hoit BD, Dorn GW 2nd, Walsh RA, Kranias EG. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest. 1996;97:533-539.
10. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res. 1994;75:401-409.
11. Slack JP, Grupp IL, Dash R, Holder D, Schmidt A, Gerst MJ, Tamura T, Tilgmann C, James PF, Johnson R, Gerdes AM, Kranias EG. The enhanced contractility of the phospholamban-deficient mouse heart persists with aging. J Mol Cell Cardiol. 2001;33:1031-1040.
12. Minamisawa S, Hoshijima M, Chu G, Ward CA, Frank K, Gu Y, Marione ME, Wang Y, Ross J Jr, Kranias EG, Giles WR, Chien KR. Chronic phospholamban- sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999;99:313-322.
13. Sato Y, Kiriazis H, Yatani A, Schmidt AG, Hahn H, Ferguson DG, Sako H, Mitarai S, Honda R, Mesnard-Rouiller L, Frank KF, Beyermann B, Wu G, Fujimori K, Dorn GW 2nd, Kranias EG. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem. 2001;276:9392-9399.
14. Haghighi K, Kolokathis F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn HS, Adamopoulos S, Liggett SB, Dorn GW 2nd, MacLennan DH, Kremastinos DT, Kranias EO. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J Clin Invest. 2003;111:869-876.
15. McConnell BK, Fatkin D, Semsarian C, Jones KA, Georgakopoulos D, Maguire CT, Healey MJ, Mudd JO, Moskowitz IP, Conner DA, Giewat M, Wakimoto H, Berul CI, Schoen FJ, Kass DA, Seidman CE, Seidman JG. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res. 2001;88:383-389.
16. Fatkin D, McConnell BK, Mudd JO, Semsarian C, Moskowitz IG, Schoen FJ, Giewat M, Seidman CE, Seidman JG. An abnormal Ca(2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyop-athy. J Clin Invest. 2000;106:1351-1359.
17. Toyofuku T, Kurzydlowski K, Tada M, MacLennan DH. Amino acids Glu2 to Ile 18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca(2+)-ATPase of sarcoplasmic reticulum. J Biol Chem. 1994;269:3088-3094.
18. Zhao W, Yuan Q, Qian J, Waggoner JR, Pathak A, Chu G, Mitton B, Sun X, Jin J, Braz JC, Hahn HS, Marreez Y, Syed F, Pollesello P, Annila A, Wang HS, Schulte Jel J, Molkentin JD, Liggett SB, Dorn GW 2nd, Kranias EG. The presence of Lys27 instead of Asn27 in human phospholamban promotes sarcoplasmic reticulum Ca(2+)-ATPase superinhibition and cardiac remodeling. Circulation. 2006;113:995-1004.
19. Engelhardt S, Hein L, Dyachenkow V, Kranias EG, Isenberg G, Lohse MJ. Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation. 2004;109:1154-1160.
20. Delling U, Sussman MA, Molkentin JD. Re-evaluating sarcoplasmic reticulum function in heart failure. Nat Med. 2000;6:942-943.
21. Song Q, Schmidt AG, Hahn HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK, Haghighi K, Seidman CE, Seidman JG, Dorn GW 2nd, Kranias EG. Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy. J Clin Invest. 2003;111:859-867.
22. Iwanaga Y, Hoshijima M, Gu Y, Iwatate M, Dieterle T, Ikeda Y, Date MO, Chrast J, Matsuzaki M, Peterson KL, Chien KR, Ross J Jr. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest. 2004;113:727-736.